Eikon Therapeutics Inc banner
E

Eikon Therapeutics Inc
NASDAQ:EIKN

Watchlist Manager
Eikon Therapeutics Inc
NASDAQ:EIKN
Watchlist
Price: 9 USD -0.11% Market Closed
Market Cap: $486.9m

Eikon Therapeutics Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Eikon Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
E
Eikon Therapeutics Inc
NASDAQ:EIKN
Research & Development
-$250.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$9.1B
CAGR 3-Years
-12%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.7B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$7.2B
CAGR 3-Years
-17%
CAGR 5-Years
-11%
CAGR 10-Years
-6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-13%
CAGR 5-Years
-14%
CAGR 10-Years
-12%
No Stocks Found

Eikon Therapeutics Inc
Glance View

Market Cap
486.9m USD
Industry
Biotechnology

Eikon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Hayward, California. The company went IPO on 2026-02-05. Eikon Therapeutics, Inc. is a United States-based drug discovery and development company. The Company’s platform allows resolution microscopy as well as the advances in biology, chemistry, engineering, and automation. The company tracks and measures the real-time movement of individual proteins in living cells to understanding of disease biology and discover differentiated therapeutics.

EIKN Intrinsic Value
6.21 USD
Overvaluation 31%
Intrinsic Value
Price $9
E

See Also

What is Eikon Therapeutics Inc's Research & Development?
Research & Development
-250.3m USD

Based on the financial report for Dec 31, 2025, Eikon Therapeutics Inc's Research & Development amounts to -250.3m USD.

What is Eikon Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 1Y
-22%

Over the last year, the Research & Development growth was -22%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett